# US 6,726,905 B1 · Poly (diallylamines)-based phosphate binders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,905 B1
- Document ID: US6726905B1
- Status: Granted
- Kind: B1
- Application number: 08/964,498
- Filed: 1997-11-05
- Granted: 2004-04-27
- Earliest claimed: 1997-11-05
- Assignees: Genzyme Corporation
- Inventors: W. Harry Mandeville, III; Stephen Randall Holmes-Farley
- Web page: https://patentgrep.com/patent/US6726905B1

## CPC

- A61K 31/787: containing heterocyclic rings having nitrogen as a ring hetero atom
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method for lowering the serum phosphate level of a patient. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer characterized by a diallylamine monomer or repeat unit. The amino nitrogen atom of the diallylamine repeat unit can be substituted by one or two substituents independently selected from among substituted and unsubstituted, normal, branched and cyclic alkyl groups, and aryl groups. When the diallylamine repeat unit comprises an ammonium or quaternary ammonium group, the monomer will further comprise a suitable anion, such as a conjugate base of a pharmaceutically acceptable acid.

## Claims

### Claim 1

A method for lowering the serum phosphate level of a patient comprising administering to the patient a therapeutically effective amount of a polymer characterized by a substituted or unsubstituted diallylamine repeat unit.

### Claim 2 (depends on 1)

The method of claim 1 wherein the polymer is a homopolymer.

### Claim 3 (depends on 1)

The method of claim 1 wherein the polymer is a copolymer.

### Claim 4 (depends on 1)

The method of claim 1 wherein the polymer is characterized by a repeat unit of the general formula
wherein R is a hydrogen atom, a substituted or unsubstituted normal, branched or cyclic alkyl group or a substituted or unsubstituted aryl group.

### Claim 5 (depends on 4)

The method of claim 4 wherein R is an alkyl or aryl substituted with one or more substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, alkyl, hydroxy, primary, secondary and tertiary amino, quaternary ammonium, alkoxy, carboxamido, sulfonamido, aryl, hydrazido, guanadyl, and ureyl.

### Claim 6 (depends on 4)

The method of claim 4 wherein R is a C1-C12-alkyl group.

### Claim 7 (depends on 6)

The method of claim 6 wherein R is an n-decyl group.

### Claim 8 (depends on 6)

The method of claim 6 wherein R is a methyl group.

### Claim 9 (depends on 1)

The method of claim 1 wherein the polymer comprises a repeat unit of the general formula
wherein R1 and R2 are each, independently, is hydrogen, a substituted or unsubstituted, normal, branched or cyclic alkyl group, or a substituted or unsubstituted aryl group; or R1, R2 and the nitrogen atom together form a cyclic system; and X− is a pharmaceutically acceptable anion.

### Claim 10 (depends on 9)

The method of claim 9 wherein X− is a conjugate base of an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, citric acid, tartaric acid, lactic acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, malic acid, succinic acid, malonic acid, sulfuric acid, L-glutamic acid, L-aspartic acid, pyruvic acid, mucic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid and acetylglycine.

### Claim 11 (depends on 9)

The method of claim 9 wherein R1 is a normal or branched C1-C12-alkyl group.

### Claim 12 (depends on 11)

The method of claim 11 wherein R1 is methyl.

### Claim 13 (depends on 12)

The method of claim 12 wherein R2 is hydrogen.

### Claim 14 (depends on 11)

The method of claim 11 wherein R1 is decyl.

### Claim 15 (depends on 14)

The method of claim 14 wherein R2 is hydrogen.

### Claim 16 (depends on 9)

The method of claim 9 wherein R1 is an alkyl or aryl group substituted with one or more substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, alkyl, hydroxy, primary, secondary and tertiary amino, quaternary ammonium, alkoxy, carboxamido, sulfonamido, aryl, hydrazido, guanadyl, and ureyl.

### Claim 17 (depends on 9)

The method of claim 9 wherein R1 and R2 together form a substituted or unsubstituted C2-C12-alkylene group.

### Claim 18 (depends on 17)

The method of claim 17 wherein R1 and R2 together form —(CH2)n—, wherein n is an integer from 2 to about 12.

### Claim 19 (depends on 1)

The method of claim 1 wherein the polymer is cross-linked.

### Claim 20 (depends on 19)

The method of claim 19 wherein the polymer is crosslinked by a multifunctional co-monomer.

### Claim 21 (depends on 20)

The method of claim 20 wherein the multifunctional co-monomer is selected from the group consisting of diacrylates, triacrylates, tetraacrylates, dimethacrylates, diacrylamides, dimethacrylamides, diallylacrylamides and polyvinylarenes.

### Claim 22 (depends on 21)

The method of claim 21 wherein the multifunctional comonomer is selected from the group consisting of ethylene glycol diacrylate, propylene glycol diacrylate, butylene glycol diacrylate, ethylene glycol dimethacrylate, butylene glycol dimethacrylate, methylene bis(methacrylamide), ethylene bis(acrylamide), ethylene bis(methacrylamide), ethylidene bis(acrylamide), ethylidene bis(methacrylamide), bisphenol A dimethacrylate, bisphenol A diacrylate, pentaerythritol tetraacrylate, trimethylolpropane triacrylate and divinylbenzene.

### Claim 23 (depends on 20)

The method of claim 20 wherein the multifunctional comonomer is a multifunctional diallylamine.

### Claim 24 (depends on 23)

The method of claim 23 wherein the multifunctional diallylamine is a bis(diallylamino)alkane or a bis(diallylalkylammonio)alkane.

### Claim 25 (depends on 24)

The method of claim 24 wherein the multifunctional diallylamine is 1,10-bis(diallylmethylammonio)decane dibromide.

### Claim 26 (depends on 19)

The method of claim 19 wherein the polymer is crosslinked by a bridging unit selected from the group consisting of straight chain or branched, substituted or unsubstituted alkylene groups, diacylalkylene groups, diacylarene groups and alkylene bis(carbamoyl) groups.

### Claim 27 (depends on 26)

The method of claim 26 wherein the bridging units are selected from the group consisting of —(CH2)n—,
wherein n is an integer from about 2 to about 20;
—CH2—CH(OH)—CH2—; —C(O)CH2CH2C(O)—;
—CH2—CH(OH)—O—(CH2)m—O—CH(OH)—CH2—, wherein m is 2 to about 4; —C(O)—(C6H2(COOH)2)—C(O)—; and
—C(O)NH(CH2)pNHC(O)—, wherein p is an integer from about 2 to about 20.

### Claim 28

A method of lowering the serum phosphate level of patient comprising administering to the patient a therapeutically effective amount of polymer comprising a first monomer of the general formula
wherein R1 and R2 are each, independently, a substituted or unsubstituted normal, branched or cyclic alkyl group or a substituted or unsubstituted aryl group; or R1, R2 and the nitrogen atom together form a cyclic system; and X− is a pharmaceutically acceptable anion; and a second monomer of the general formula
wherein R is a hydrogen atom, a substituted or unsubstituted normal, branched or cyclic alkyl group or a substituted or unsubstituted aryl group.
